Aevi Genomic Medicine, Inc. Receives Positive Nasdaq Listing Determination
Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
Aevi Genomic Medicine to Present at the 2019 Wedbush PacGrow Healthcare Conference
Leaders in genetic science and commercial drug development
Discover the future of novel genetic therapies currently being researched by Aevi Genomic Medicine.
Presentations, information, and news